Portal de investigação
Recency of Heart Failure Hospitalization, Outcomes, and the Effect of Empagliflozin An EMPEROR-Pooled Analysis
Data de publicação:
Data Ahead of Print:
Autores da FMUP
Participantes de fora da FMUP
- Zannad, F
- Butler, J
- Filippatos, G
- Pocock, S
- Iwata, T
- Sumin, M
- Zeller, C
- Januzzi, JL
- Anker, SD
- Packer, M
Unidades de investigação
Abstract
BACKGROUND Patients with a recent heart failure (HF) hospitalization have a high risk of rehospitalization and mortality. Early treatment may have a substantial impact on patient outcomes. OBJECTIVES This study sought to study the outcomes and effect of empagliflozin according to timing of prior HF hospitalization. METHODS EMPEROR-Pooled (EMPEROR-Reduced [EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction] and EMPEROR-Preserved [EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction] combined) included 9,718 HF patients who were grouped according to the recency of HF hospitalization (none, <3 months, 3-6 months, 6-12 months, >12 months). The primary outcome was a composite of time to first of HF hospitalization or cardiovascular death, over a median follow-up of 21 months. RESULTS The primary outcome event rates (per 100 person-years) in the placebo group were 26.7, 18.1, 13.7, and 2.8 for patients hospitalized within 3 months, 3-6 months, 6-12 months, and >12 months, respectively. The relative risk reduction of primary outcome events with empagliflozin was similar across HF hospitalization categories (P interaction = 0.67). The primary outcome absolute risk reduction was more pronounced among patients with a recent HF hospitalization but without statistical heterogeneity of treatment effect: -6.9, -5.5, -0.8, and -0.6 events prevented per 100 person-years for patients hospitalized within <3 months, 3-6 months, 6-12 months, and >12 months, respectively, and -2.4 events prevented per 100 person-years of follow-up in those without a prior HF hospitalization (P interaction = 0.64). Empagliflozin was safe irrespective of HF hospitalization recency. CONCLUSIONS Patients with a recent HF hospitalization have a high risk of events. Empagliflozin reduced HF events regardless of HF hospitalization recency. (c) 2023 by the American College of Cardiology Foundation. Published by Elsevier. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Dados da publicação
- ISSN/ISSNe:
- 2213-1787, 2213-1779
- Tipo:
- Article
- Páginas:
- 702-712
- Link para outro recurso:
- www.scopus.com
JACC-HEART FAILURE Elsevier BV
Citações Recebidas na Web of Science: 1
Citações Recebidas na Scopus: 6
Documentos
- Não há documentos
Filiações
Keywords
- empagliflozin; heart failure hospitalization recency; risk
Financiamento
Proyectos asociados
Dapagliflozin, Spironolactone or Both for HFpEF (SOGALDI-PEF) - NCT05676684
Investigador Principal: João Pedro Melo Marques Pinho Ferreira
Ensaio Clínico Académico (SOGALDI-PEF) . AstraZeneca . 2022
Citar a publicação
Ferreira JP,Zannad F,Butler J,Filippatos G,Pocock S,Iwata T,Sumin M,Zeller C,Januzzi JL,Anker SD,Packer M. Recency of Heart Failure Hospitalization, Outcomes, and the Effect of Empagliflozin An EMPEROR-Pooled Analysis. JACC Heart Fail. 2023. 11. (6):p. 702-712. IF:13,000. (1).
